Literature DB >> 2206793

Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease.

O Gudjonsson, E Sanz, G Alván, S M Aquilonius, J Reviriego.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2206793      PMCID： PMC1368233          DOI： 10.1111/j.1365-2125.1990.tb03780.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.

Authors:  E Steiner; L Bertilsson; J Säwe; I Bertling; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1988-10       Impact factor: 6.875

2.  Predicting Parkinson's disease.

Authors:  S H Snyder; R J D'Amato
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

3.  Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs.

Authors:  J Poirier; M Roy; G Campanella; T Cloutier; S Paris
Journal:  Lancet       Date:  1987-08-15       Impact factor: 79.321

4.  Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.

Authors:  A Barbeau; T Cloutier; M Roy; L Plasse; S Paris; J Poirier
Journal:  Lancet       Date:  1985-11-30       Impact factor: 79.321

Review 5.  The metabolism of insecticides: the role of monooxygenase enzymes.

Authors:  A P Kulkarni; E Hodgson
Journal:  Annu Rev Pharmacol Toxicol       Date:  1984       Impact factor: 13.820

6.  Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

Authors:  G C Davis; A C Williams; S P Markey; M H Ebert; E D Caine; C M Reichert; I J Kopin
Journal:  Psychiatry Res       Date:  1979-12       Impact factor: 3.222

7.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

Authors:  J W Langston; P Ballard; J W Tetrud; I Irwin
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

8.  Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography.

Authors:  P J Wedlund; B J Sweetman; C B McAllister; R A Branch; G R Wilkinson
Journal:  J Chromatogr       Date:  1984-04-13

9.  Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in Rana pipiens.

Authors:  A Barbeau; L Dallaire; N T Buu; J Poirier; E Rucinska
Journal:  Life Sci       Date:  1985-10-21       Impact factor: 5.037

10.  MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.

Authors:  R Fonne-Pfister; M J Bargetzi; U A Meyer
Journal:  Biochem Biophys Res Commun       Date:  1987-11-13       Impact factor: 3.575
View more
  1 in total

1.  Acetaldehyde and parkinsonism: role of CYP450 2E1.

Authors:  Francesca Vaglini; Cristina Viaggi; Valentina Piro; Carla Pardini; Claudio Gerace; Marco Scarselli; Giovanni Umberto Corsini
Journal:  Front Behav Neurosci       Date:  2013-06-21       Impact factor: 3.558
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.